Regulus Therapeutics (RGLS) Misses Q2 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $2.49 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
• NVE Corporation names new CEO and expands board to seven members